Cargando…

Post‐Covid‐19‐vaccination adverse events and healthcare utilization among individuals with or without previous SARS‐CoV‐2 infection

BACKGROUND: Post‐marketing pharmacovigilance data are scant on the safety of Covid‐19 vaccines among people with previous SARS‐CoV‐2 infection compared with ordinary vaccine recipients. We compared the post‐vaccination adverse events of special interests (AESI), accident and emergency room (A&E)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Francisco Tsz Tsun, Huang, Lei, Peng, Kuan, Li, Xue, Chui, Celine Sze Ling, Wan, Eric Yuk Fai, Wong, Carlos King Ho, Chan, Esther Wai Yin, Hung, Ivan Fan Ngai, Wong, Ian Chi Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303328/
https://www.ncbi.nlm.nih.gov/pubmed/35043503
http://dx.doi.org/10.1111/joim.13453
_version_ 1784751837222535168
author Lai, Francisco Tsz Tsun
Huang, Lei
Peng, Kuan
Li, Xue
Chui, Celine Sze Ling
Wan, Eric Yuk Fai
Wong, Carlos King Ho
Chan, Esther Wai Yin
Hung, Ivan Fan Ngai
Wong, Ian Chi Kei
author_facet Lai, Francisco Tsz Tsun
Huang, Lei
Peng, Kuan
Li, Xue
Chui, Celine Sze Ling
Wan, Eric Yuk Fai
Wong, Carlos King Ho
Chan, Esther Wai Yin
Hung, Ivan Fan Ngai
Wong, Ian Chi Kei
author_sort Lai, Francisco Tsz Tsun
collection PubMed
description BACKGROUND: Post‐marketing pharmacovigilance data are scant on the safety of Covid‐19 vaccines among people with previous SARS‐CoV‐2 infection compared with ordinary vaccine recipients. We compared the post‐vaccination adverse events of special interests (AESI), accident and emergency room (A&E) visit, and hospitalization between these two groups. METHODS: We conducted a retrospective cohort study using a territory‐wide public healthcare database with population‐based vaccination records in Hong Kong. RESULTS: In total, 3922 vaccine recipients with previous SARS‑CoV‑2 infection and 1,137,583 vaccine recipients without previous SARS‑CoV‑2 infection were included. No significant association was observed between previous SARS‑CoV‑2 infection and AESI or hospitalization. Previous SARS‑CoV‑2 infection was significantly associated with a lower risk of A&E visit (CoronaVac: hazard ratios [HR] = 0.56, 95% confidence intervals [CI]: 0.32–0.99; Comirnaty: HR = 0.62, 95% CI: 0.47–0.82). CONCLUSION: No safety signal of Covid‐19 vaccination was detected from the comparison between vaccine recipients with previous SARS‐CoV‐2 infection and those without infection.
format Online
Article
Text
id pubmed-9303328
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93033282022-07-22 Post‐Covid‐19‐vaccination adverse events and healthcare utilization among individuals with or without previous SARS‐CoV‐2 infection Lai, Francisco Tsz Tsun Huang, Lei Peng, Kuan Li, Xue Chui, Celine Sze Ling Wan, Eric Yuk Fai Wong, Carlos King Ho Chan, Esther Wai Yin Hung, Ivan Fan Ngai Wong, Ian Chi Kei J Intern Med Brief Reports BACKGROUND: Post‐marketing pharmacovigilance data are scant on the safety of Covid‐19 vaccines among people with previous SARS‐CoV‐2 infection compared with ordinary vaccine recipients. We compared the post‐vaccination adverse events of special interests (AESI), accident and emergency room (A&E) visit, and hospitalization between these two groups. METHODS: We conducted a retrospective cohort study using a territory‐wide public healthcare database with population‐based vaccination records in Hong Kong. RESULTS: In total, 3922 vaccine recipients with previous SARS‑CoV‑2 infection and 1,137,583 vaccine recipients without previous SARS‑CoV‑2 infection were included. No significant association was observed between previous SARS‑CoV‑2 infection and AESI or hospitalization. Previous SARS‑CoV‑2 infection was significantly associated with a lower risk of A&E visit (CoronaVac: hazard ratios [HR] = 0.56, 95% confidence intervals [CI]: 0.32–0.99; Comirnaty: HR = 0.62, 95% CI: 0.47–0.82). CONCLUSION: No safety signal of Covid‐19 vaccination was detected from the comparison between vaccine recipients with previous SARS‐CoV‐2 infection and those without infection. John Wiley and Sons Inc. 2022-02-01 2022-06 /pmc/articles/PMC9303328/ /pubmed/35043503 http://dx.doi.org/10.1111/joim.13453 Text en © 2022 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Reports
Lai, Francisco Tsz Tsun
Huang, Lei
Peng, Kuan
Li, Xue
Chui, Celine Sze Ling
Wan, Eric Yuk Fai
Wong, Carlos King Ho
Chan, Esther Wai Yin
Hung, Ivan Fan Ngai
Wong, Ian Chi Kei
Post‐Covid‐19‐vaccination adverse events and healthcare utilization among individuals with or without previous SARS‐CoV‐2 infection
title Post‐Covid‐19‐vaccination adverse events and healthcare utilization among individuals with or without previous SARS‐CoV‐2 infection
title_full Post‐Covid‐19‐vaccination adverse events and healthcare utilization among individuals with or without previous SARS‐CoV‐2 infection
title_fullStr Post‐Covid‐19‐vaccination adverse events and healthcare utilization among individuals with or without previous SARS‐CoV‐2 infection
title_full_unstemmed Post‐Covid‐19‐vaccination adverse events and healthcare utilization among individuals with or without previous SARS‐CoV‐2 infection
title_short Post‐Covid‐19‐vaccination adverse events and healthcare utilization among individuals with or without previous SARS‐CoV‐2 infection
title_sort post‐covid‐19‐vaccination adverse events and healthcare utilization among individuals with or without previous sars‐cov‐2 infection
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303328/
https://www.ncbi.nlm.nih.gov/pubmed/35043503
http://dx.doi.org/10.1111/joim.13453
work_keys_str_mv AT laifranciscotsztsun postcovid19vaccinationadverseeventsandhealthcareutilizationamongindividualswithorwithoutprevioussarscov2infection
AT huanglei postcovid19vaccinationadverseeventsandhealthcareutilizationamongindividualswithorwithoutprevioussarscov2infection
AT pengkuan postcovid19vaccinationadverseeventsandhealthcareutilizationamongindividualswithorwithoutprevioussarscov2infection
AT lixue postcovid19vaccinationadverseeventsandhealthcareutilizationamongindividualswithorwithoutprevioussarscov2infection
AT chuicelineszeling postcovid19vaccinationadverseeventsandhealthcareutilizationamongindividualswithorwithoutprevioussarscov2infection
AT wanericyukfai postcovid19vaccinationadverseeventsandhealthcareutilizationamongindividualswithorwithoutprevioussarscov2infection
AT wongcarloskingho postcovid19vaccinationadverseeventsandhealthcareutilizationamongindividualswithorwithoutprevioussarscov2infection
AT chanestherwaiyin postcovid19vaccinationadverseeventsandhealthcareutilizationamongindividualswithorwithoutprevioussarscov2infection
AT hungivanfanngai postcovid19vaccinationadverseeventsandhealthcareutilizationamongindividualswithorwithoutprevioussarscov2infection
AT wongianchikei postcovid19vaccinationadverseeventsandhealthcareutilizationamongindividualswithorwithoutprevioussarscov2infection